含新型重组抗原的葡聚糖颗粒疫苗保护小鼠抵抗实验性隐球菌病
研究旨在发现更多可提供疫苗保护的新型隐球菌抗原。选取16种蛋白重组表达并加载至葡聚糖颗粒(GP)疫苗,BALB/c与C57BL/6小鼠接受三次皮下注射后经致死性气管内攻毒观察84天生存。鉴定出7种新蛋白可保护BALB/c和/或C57BL/6小鼠,将保护性抗原库扩大至11种,并显示高转录胞外蛋白可作疫苗靶点。
要点
- 16种候选蛋白制成GP疫苗,7种新蛋白对BALB/c和/或C57BL/6小鼠具保护作用。
- BALB/c小鼠存活通常优于C57BL/6小鼠。
- 保护性抗原库扩展至11种蛋白,GP亚单位疫苗显示效力。
核心结论
- 鉴定出7种新蛋白作为GP疫苗可保护BALB/c和/或C57BL/6小鼠抵抗隐球菌感染,将保护性抗原库扩大至11种蛋白。
- 高转录的胞外蛋白可作为抗隐球菌疫苗靶点,GP亚单位疫苗显示效力,并鉴定出可用于多表位疫苗进一步测试的候选抗原。
研究设计与样本
- 研究将16种具胞外证据的蛋白在E. coli中重组表达、纯化并加载至葡聚糖颗粒(GP),BALB/c与C57BL/6小鼠接受三次皮下注射,经致死性气管内攻毒后评估84天生存。
主要发现
- 与已发表的6种GP疫苗一致,BALB/c小鼠总体保护通常优于C57BL/6小鼠。
- 7种新蛋白以GP疫苗形式给予时保护BALB/c和/或C57BL/6小鼠抵抗隐球菌感染。
- 保护性抗原库由原有6种扩大至11种蛋白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningitis due to Cryptococcus neoformans is responsible for upwards of 180,000 deaths worldwide annually, mostly in immunocompromised individuals. Currently there are no licensed fungal vaccines, and even with anti-fungal drug treatment, cryptococcal meningitis is often fatal. Our lab previously demonstrated vaccination with recombinant cryptococcal proteins delivered in glucan particles (GPs) protects mice against an otherwise lethal infection. The aim of the present study was to discover additional cryptococcal antigens affording vaccine-mediated protection. Sixteen proteins, each with evidence of extracellularity, were selected for in vivo testing based on their abundance in protective alkaline extracts of an acapsular C. neoformans strain, their known immunogenicity, and/or their high transcript level during human infection. Candidate antigens were recombinantly expressed in E. coli, purified and loaded into GPs. BALB/c and C57BL/6 mice received three subcutaneous injections of GP-based vaccine, and survival was assessed for 84 days following a lethal orotracheal challenge with strain KN99. As with our six published GP-vaccines, we saw differences in overall protection between mouse strains such that BALB/c mice typically demonstrated better survival than C57BL/6 mice. From these studies, we identified seven new proteins which, when administered as GP-vaccines, protect BALB/c and/or C57BL/6 mice against cryptococcal infection. With these results, we expand the pool of novel protective antigens to eleven proteins and demonstrate the potential for selection of highly transcribed extracellular proteins as vaccine targets. These screens highlight the efficacy of GP-subunit vaccines and identify promising antigens for further testing in anti-cryptococcal, multi-epitope vaccine formulations.
引用
- Hester MM, Lee CK, Abraham A, et al. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. Vaccine. 2019. PMID: 31699504. doi:10.1016/j.vaccine.2019.10.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。